(2023). Consultation Rate and Mode by Deprivation in English General Practice From 2018 to 2022: Population-Based Study. Jmir Public Health Surveill, 9, e44944. http://doi.org/10.2196/44944.
(2023). External validation of the QLifetime cardiovascular risk prediction tool: population cohort study. Bmc Cardiovasc Disord, 23, 194. http://doi.org/10.1186/s12872-023-03209-8.
(2023). Underlying cancer risk among patients with fatigue and other vague symptoms: a population-based cohort study in primary care. Br J Gen Pract, 73, e75-e87. http://doi.org/10.3399/bjgp.2022.0371.
(2023). Trends in antipsychotic prescribing to children and adolescents in England: cohort study using 2000-19 primary care data. Lancet Psychiatry, 10, 119-128. http://doi.org/10.1016/s2215-0366(22)00404-7.
(2023). Derivation and validation of the CFracture competing risk fracture prediction tool compared with QFracture in older people and people with comorbidity: a population cohort study. Lancet Healthy Longev, 4, e43-e53. http://doi.org/10.1016/s2666-7568(22)00290-2.
(2023). Analysis of Mortality Among Transgender and Gender Diverse Adults in England. Jama Netw Open, 6, e2253687. http://doi.org/10.1001/jamanetworkopen.2022.53687.
(2022). Novel multimorbidity clusters in people with eczema and asthma: a population-based cluster analysis. Sci Rep, 12, 21866. http://doi.org/10.1038/s41598-022-26357-x.
(2022). Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. Lancet Digit Health, 4, e873-e883. http://doi.org/10.1016/s2589-7500(22)00174-1.
(2022). Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling. Health Technol Assess, 26, 1-310. http://doi.org/10.3310/zuce8371.
(2022). Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet, 400, 733-743. http://doi.org/10.1016/s0140-6736(22)01349-6.